CD44 and hematologic disorder: Our fabricated A6 peptide functionalized nanoparticles with CD44 and Hsp90 targets are expected to possess a broad anti-cancer spectrum both in hematological malignancies and solid tumors, which are rarely reported in nanomedicines.